2 Information about brentuximab vedotin

Marketing authorisation indication

2.1 Brentuximab vedotin (Adcetris) is indicated for treating relapsed or refractory CD30‑positive Hodgkin lymphoma in adults:

  • after autologous stem cell transplant or

  • after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option

  • at increased risk of relapse or progression after autologous stem cell transplant.

Dosage in the marketing authorisation

2.2 The recommended dose is 1.8 mg/kg administered by intravenous infusion over 30 minutes every 3 weeks.


2.3 The price of brentuximab vedotin is £2,500 for a 50‑mg vial (excluding VAT; British national formulary edition 69). The company has a commercial arrangement. This makes brentuximab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.'

  • National Institute for Health and Care Excellence (NICE)